Analysis of safety and efficacy of proton radiotherapy for optic nerve sheath meningioma.

IF 3.7 Q1 CLINICAL NEUROLOGY Neuro-oncology advances Pub Date : 2024-09-21 eCollection Date: 2024-01-01 DOI:10.1093/noajnl/vdae160
Maximilian Y Deng, Sophie Rauh, Günes Anil, Jonathan W Lischalk, Laura Hahnemann, Tanja Eichkorn, Juliane Hörner-Rieber, Angela Paul, Elisabetta Sandrini, Philipp Hoegen-Sassmannshausen, Thomas Held, Sebastian Regnery, Lukas Bauer, Felix Sahm, Andreas von Deimling, Antje Wick, Wolfgang Wick, Christine Jungk, Sandro M Krieg, Klaus Herfarth, Jürgen Debus, Laila König
{"title":"Analysis of safety and efficacy of proton radiotherapy for optic nerve sheath meningioma.","authors":"Maximilian Y Deng, Sophie Rauh, Günes Anil, Jonathan W Lischalk, Laura Hahnemann, Tanja Eichkorn, Juliane Hörner-Rieber, Angela Paul, Elisabetta Sandrini, Philipp Hoegen-Sassmannshausen, Thomas Held, Sebastian Regnery, Lukas Bauer, Felix Sahm, Andreas von Deimling, Antje Wick, Wolfgang Wick, Christine Jungk, Sandro M Krieg, Klaus Herfarth, Jürgen Debus, Laila König","doi":"10.1093/noajnl/vdae160","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Primary optic nerve sheath meningiomas (ONSMs) represent a group of benign tumors originating from the optic nerve sheath, typically causing painless, gradual onset monocular visual loss, which can result in blindness if left untreated. Radiation therapy represents an important treatment option for patients with ONSM, allowing for preservation and potential improvement in visual function. In particular, proton radiotherapy may enable a reduction of the side effects due to its physical advantage of an inverted dose profile with a steep dose gradient. The study investigates the visual acuity, local tumor control, and treatment-related toxicities following proton beam radiotherapy with a single institutional cohort comprising 32 patients treated for ONSM.</p><p><strong>Methods: </strong>Patients with primary ONSM, either histologically (16/32) or radiologically confirmed (16/32), which were treated at the Department of Radiation Oncology at the University Hospital Heidelberg (Germany) were assessed in regard to their visual outcomes, treatment toxicity, and local tumor control following radiotherapy according to response assessment in neuro-oncology criteria.</p><p><strong>Results: </strong>After a median follow-up time of 39.5 months, the 5-year local progression-free survival was estimated at 100%, with 84.4% of patients reporting improvement or stability in visual acuity during their last follow-up. Radiation-induced optic neuropathy (RION) was encountered in 9.4%.</p><p><strong>Conclusions: </strong>Our study demonstrates proton beam therapy as a safe and effective treatment alternative in the therapeutic management of ONSMs. RION represents a rare but dreaded complication after treatment. Future head-to-head comparisons with photon radiotherapy in a prospective setting are required to demonstrate a potential, additional clinical benefit.</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":null,"pages":null},"PeriodicalIF":3.7000,"publicationDate":"2024-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11491494/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuro-oncology advances","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/noajnl/vdae160","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Primary optic nerve sheath meningiomas (ONSMs) represent a group of benign tumors originating from the optic nerve sheath, typically causing painless, gradual onset monocular visual loss, which can result in blindness if left untreated. Radiation therapy represents an important treatment option for patients with ONSM, allowing for preservation and potential improvement in visual function. In particular, proton radiotherapy may enable a reduction of the side effects due to its physical advantage of an inverted dose profile with a steep dose gradient. The study investigates the visual acuity, local tumor control, and treatment-related toxicities following proton beam radiotherapy with a single institutional cohort comprising 32 patients treated for ONSM.

Methods: Patients with primary ONSM, either histologically (16/32) or radiologically confirmed (16/32), which were treated at the Department of Radiation Oncology at the University Hospital Heidelberg (Germany) were assessed in regard to their visual outcomes, treatment toxicity, and local tumor control following radiotherapy according to response assessment in neuro-oncology criteria.

Results: After a median follow-up time of 39.5 months, the 5-year local progression-free survival was estimated at 100%, with 84.4% of patients reporting improvement or stability in visual acuity during their last follow-up. Radiation-induced optic neuropathy (RION) was encountered in 9.4%.

Conclusions: Our study demonstrates proton beam therapy as a safe and effective treatment alternative in the therapeutic management of ONSMs. RION represents a rare but dreaded complication after treatment. Future head-to-head comparisons with photon radiotherapy in a prospective setting are required to demonstrate a potential, additional clinical benefit.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
质子放射治疗视神经鞘脑膜瘤的安全性和有效性分析。
背景:原发性视神经鞘脑膜瘤(ONSMs)是一组起源于视神经鞘的良性肿瘤,通常会引起无痛性、渐进性的单眼视力下降,如果不及时治疗,可能会导致失明。放射治疗是 ONSM 患者的一种重要治疗选择,可以保护和改善患者的视功能。特别是质子放射治疗,由于其具有倒剂量曲线和陡峭剂量梯度的物理优势,可以减少副作用。该研究调查了质子束放疗后的视力、局部肿瘤控制和治疗相关毒性反应,研究对象是由 32 名 ONSM 患者组成的单一机构队列:方法:根据神经肿瘤学反应评估标准,对在海德堡大学医院(德国)放射肿瘤科接受治疗的原发性ONSM患者(组织学确诊(16/32)或放射学确诊(16/32))的视力结果、治疗毒性以及放疗后的局部肿瘤控制情况进行评估:中位随访时间为 39.5 个月,5 年局部无进展生存率估计为 100%,84.4% 的患者在最后一次随访中报告视力有所改善或稳定。9.4%的患者出现了放射诱导性视神经病变(RION):我们的研究表明,质子束疗法是治疗ONSMs的一种安全有效的替代疗法。RION是治疗后一种罕见但可怕的并发症。未来需要在前瞻性环境中与光子放疗进行头对头比较,以证明其潜在的额外临床益处。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.20
自引率
0.00%
发文量
0
审稿时长
12 weeks
期刊最新文献
International symposium on inheritable central nervous system (CNS) cancer predisposition: A prologue. Correction to: Effect of bevacizumab on refractory meningiomas: 3D volumetric growth rate versus response assessment in neuro-oncology criteria. Effect of antibiotic drug use on outcome and therapy-related toxicity in patients with glioblastoma-A retrospective cohort study. Empowering the next generation in neuro-oncology: Introduction of the EANO Career Boost Initiative. A phase 1 dose escalation of pritumumab in patients with refractory or recurrent gliomas or brain metastases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1